Loading clinical trials...

Efficacy of Vonoprazan Based Dual and Triple Therapy for Patient With Helicobacter Pylori Infection | Clinical Trials | Clareo Health

RECRUITINGNA

Efficacy of Vonoprazan Based Dual and Triple Therapy for Patient With Helicobacter Pylori Infection

Efficacy of Vonoprazan Based Dual and Triple Therapy for Naive Patient With Helicobacter Pylori Infection

NCT07045688•Sohag University

View on ClinicalTrials.gov

Summary

This study aims to assess Efficacy of vonoprazan based dual and triple therapy for naïve patient with Helicopacter Pylori infection in Sohag Government .

Eligibility

Age

19 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Age: \>18 years old.
•H. pylori infection: Confirmed by histopathology or non-invasive tests (e.g., stool antigen test).

Exclusion Criteria

•Prior H. pylori treatment: Previous treatment for H. pylori infection.
•Allergies: Known allergies to study medications or components.
•Patients cannot finish treatment course.
•Patient missed follow up.
•Patients refusing or neglecting test of cure for H. pylori.

Locations (1)

Sohag University Hospital

Sohag, Egypt

Key Dates

Start Date

May 13, 2025

Primary Completion Date

November 25, 2025

Completion Date

November 25, 2025

Last Updated

July 1, 2025

Enrollment

150

ESTIMATED participants

Conditions

H. Pylori Infection

Interventions

Efficacy of Vonoprazan based dual therapy for naive patient with Helicobacter Pylori infection

DRUG

Efficacy of Vonoprazan based triple therapy for naive patient with Helicobacter Pylori infection

DRUG

Efficacy of PPI based triple therapy for naive patient with Helicobacter Pylori infection

DRUG

Contacts

Andrew K Wadea, Resident

CONTACT

01211498813 andrewkameel511@gmail.com

Hamdy S Mohammed, Professor

CONTACT

01111101934

Early Detection and Screening Strategy of Gatric Cancer in Sichuan Province-A Prospective Cohort Study (WCH-GC-SIGES-01)

NCT03597672

Neoplasm, StomachH. Pylori Infection+1 more

View study

COMPLETEDPHASE3

Efficacy of TAK-438, Amoxicillin and Clarithromycin in the First Line Eradication of H. Pylori

NCT01505127

H. Pylori Infection

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 1, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Efficacy of Vonoprazan Based Dual and Triple Therapy for Patient With Helicobacter Pylori Infection

Inclusion Criteria

Exclusion Criteria

Early Detection and Screening Strategy of Gatric Cancer in Sichuan Province-A Prospective Cohort Study (WCH-GC-SIGES-01)

Efficacy of TAK-438, Amoxicillin and Clarithromycin in the First Line Eradication of H. Pylori

The Efficacy of Sequential Therapy as Second Line Therapy for Refractory Helicobacter Pylori Infection - A Pilot Study

Establish Epidemiologic Data of H. Pylori Infection in Children and Adolescents-Using C13-UBT